Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Cash (2020 - 2025)

Historic Change in Cash for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $109.1 million.

  • Apellis Pharmaceuticals' Change in Cash rose 19647.39% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 24904.27%. This contributed to the annual value of $60.3 million for FY2024, which is 13004.01% up from last year.
  • Apellis Pharmaceuticals' Change in Cash amounted to $109.1 million in Q3 2025, which was up 19647.39% from $11.6 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Change in Cash high stood at $356.4 million for Q4 2021, and its period low was -$300.1 million during Q1 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Change in Cash value was -$6.7 million (recorded in 2022), while the average stood at -$4.5 million.
  • Over the last 5 years, Apellis Pharmaceuticals' Change in Cash had its largest YoY gain of 326396.68% in 2023, and its largest YoY loss of 70683.51% in 2023.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Change in Cash stood at $356.4 million in 2021, then crashed by 109.08% to -$32.4 million in 2022, then tumbled by 212.6% to -$101.2 million in 2023, then soared by 114.2% to $14.4 million in 2024, then surged by 659.2% to $109.1 million in 2025.
  • Its last three reported values are $109.1 million in Q3 2025, $11.6 million for Q2 2025, and -$52.8 million during Q1 2025.